Skip to content
OVCAR-8
Tissue
Ovary
Disease
Ovarian adenocarcinoma
Synonyms
OVCAR 8, NIH:OVCAR-8, OVCAR8, Ovcar8, OVCAR.8, OVCA8, OVCAR-8/EGFP_LC3

Documents

OVCAR-8

Cell line · Product number 305383

OVCAR-8 is a human ovarian carcinoma cell line established from a patient with advanced-stage ovarian adenocarcinoma. This cell line is particularly noted...

US$650.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
  • CoA
1

01General information

Description

OVCAR-8 is a human ovarian carcinoma cell line established from a patient with advanced-stage ovarian adenocarcinoma. This cell line is particularly noted for its significant resistance to cisplatin and carboplatin, which were administered in high doses during the patient’s treatment. OVCAR-8 is widely utilized in research investigating mechanisms of chemoresistance in ovarian cancer, as well as in the development of strategies to overcome resistance to platinum-based chemotherapies.

OVCAR-8 cells exhibit an epithelial morphology and grow adherently in culture. The cell line is characterized by molecular and phenotypic traits associated with high-grade ovarian cancers, including alterations in DNA damage repair mechanisms and other pathways contributing to tumor survival under chemotherapeutic stress. Unlike some other ovarian cancer cell lines, OVCAR-8 does not exhibit detectable expression of metallothionein, a protein thought to play a role in resistance to heavy metal-based drugs. However, this cell line demonstrates cross-resistance to cadmium and other agents, suggesting the involvement of alternative resistance mechanisms, such as increased glutathione levels and enhanced DNA repair capacity.

OVCAR-8 is a valuable tool in preclinical research for screening chemotherapeutic agents, evaluating targeted therapies, and studying the biology of chemoresistance. Researchers employ this cell line to explore combinations of drugs designed to sensitize resistant tumors to standard treatments. Additionally, OVCAR-8 provides insights into the genetic and molecular adaptations of ovarian cancer cells that underlie their survival and persistence despite aggressive chemotherapy regimens. Its clinical relevance and resistance profile make it an important resource for advancing ovarian cancer research and therapy development.

Tissue
Ovary
Disease
Ovarian adenocarcinoma
Synonyms
  • OVCAR 8
  • NIH:OVCAR-8
  • OVCAR8
  • Ovcar8
  • OVCAR.8
  • OVCA8
  • OVCAR-8/EGFP_LC3

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent
Biosafety level
1

03Characteristics

Morphology
Epithelial-like
Doubling time
24-32 hours

04Identifiers

Citation
OVCAR-8 (Cytion catalog number 305383)
NCBI TaxID
9606
Cellosaurus
CVCL_1629

05Expression and susceptibility

Mutational profile
Mutation: CTNNB1, Simple, p.Gln26Arg (c.77A>G), Heterozygous; Mutation: ERBB2, Simple, p.Gly776Val (c.2327G>T), Heterozygous; Mutation: KRAS, Simple, p.Pro121His (c.362C>A), Heterozygous; Mutation: TP53, Simple, c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21), Homozygous, Splice acceptor mutation

06Handling and culture

Culture medium
RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with 10% FBS
Dissociation reagent
Accutase
Seeding density
3-4 x 104 cells/mL
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Freeze medium
As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
64 years
Ethnicity
Caucasian